MapLight Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPLT research report →
Range $13 – $46
Price Chart
About the company
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis.
- CEO
- Christopher A. Kroeger
- IPO
- 2025
- Employees
- 133
- HQ
- Redwood City, CA, US
Get TickerSpark's AI analysis on MPLT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $411.21M
- P/E
- -1.87
- PEG
- 0.03
- P/S
- 0.00
- P/B
- 1.26
- EV/EBITDA
- -1.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -63.84%
- ROIC
- -69.35%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-578,000+17.5%
- Op Income
- $-169,083,000
- Net Income
- $-161,152,000-107.7%
- EPS
- $-3.66-95.7%
- OCF Growth
- -75.3%
- FCF Growth
- -74.2%
- 52W High
- $40.43
- 52W Low
- $8.92
- 50D MA
- $11.99
- 200D MA
- $21.45
- Beta
- 2.77
- RSI (14)
- 31
- Avg Volume
- 866.01K
No earnings-call transcripts are available for MPLT yet.
- Free Float
- 18.8%
- Shares Outstanding
- 42.44M
- Float Shares
- 7.97M
of shares held by institutions
81 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Novo Holdings A/S | 3.69M | 0 |
| Fcpm Iii Services B.V. | 3.23M | 0 |
| T. Rowe Price Investment Management, Inc. | 2.78M | ▼ 20.21K |
| Goldman Sachs Group Inc | 1.95M | ▼ 46.56K |
| Price T Rowe Associates Inc | 1.42M | ▲ 1.31M |
| Blackrock, Inc. | 1.03M | ▼ 314.60K |
| Nan Fung Group Holdings Ltd | 971.25K | 0 |
| 5am Venture Management, LLC | 950.01K | 0 |
| Sanofi | 912.04K | 0 |
| Vanguard Group Inc | 869.67K | ▲ 869.67K |
| State Street Corp | 852.15K | ▲ 513.03K |
| Fmr LLC | 823.56K | ▲ 619.05K |
Held by 118 ETFs
Biggest fund positions in MPLT by dollar value.
Our MPLT coverage
Recent articles, reports, and earnings notes.
No research on MPLT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MPLT report →MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
globenewswire.com · Oct 6
MapLight Therapeutics to Participate in Upcoming Investor Conference
globenewswire.com · Sep 9
BlackRock Inc. Takes $36.74 Million Position in Maplight Therapeutics, Inc. $MPLT
defenseworld.net · Sep 2
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com · Aug 13
MapLight Therapeutics Announces $150 Million Private Placement Financing
globenewswire.com · Aug 13
MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
prnewswire.com · Aug 3
Maplight Therapeutics (NASDAQ:MPLT) Trading 18.2% Higher on Insider Buying Activity
defenseworld.net · Jul 30
ADAR1 Capital Management LLC Purchases New Position in Maplight Therapeutics, Inc. $MPLT
defenseworld.net · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.